Loading resource…

Suchira Gallage, Olivier Govaere, Quentin M. Anstee, Gerald I. Shulman, Frank Tacke, Mathias Heikenwalder
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that poses risks for cirrhosis and hepatocellular carcinoma, as well as extrahepatic complications. Recent clinical trials have introduced new pharmacological treatments, including THRβ agonists and GLP-1R agonists, which have shown promise for patients with non-cirrhotic MASH. The document emphasizes the heterogeneity of MASH and the importance of tailored treatment strategies that may include lifestyle changes and combinatorial pharmacotherapy.
No account needed